Increasing Prevalence & Incidence rates for Alzheimer’s in Americans, report states

alzheimer9182

As per a new report published recently, “2018 Alzheimer’s Disease Facts And Figures”, the prevalence, incidence and mortality rates for Alzheimer’s disease in Americans are on a sharp increasing trend.

Increasing Prevalence and Incidence:

As per the report published on Alzheimer’s Association website, The number of Americans living with Alzheimer’s is growing — and growing fast. An estimated 5.7 million Americans of all ages have Alzheimer’s.

An estimated 5.7 million Americans of all ages are living with Alzheimer’s dementia in 2018. This number includes an estimated 5.5 million people age 65 and older and approximately 200,000 individuals under age 65 who have younger-onset Alzheimer’s.

  • One in 10 people age 65 and older (10 percent) has Alzheimer’s dementia.
  • Almost two-thirds of Americans with Alzheimer’s are women.
  • Older African-Americans are about twice as likely to have Alzheimer’s or other dementias as older whites.
  • Hispanics are about one and one-half times as likely to have Alzheimer’s or other dementias as older whites.

As the number of older Americans grows rapidly, so too will the numbers of new and existing cases of Alzheimer’s. Today, someone in the United States develops Alzheimer’s every 65 seconds. By mid-century, someone in the United States will develop the disease every 33 seconds.

Increasing Mortality:

The report further states that Alzheimer’s disease is the only top 10 cause of death in the United States that cannot be prevented, cured or even slowed.

  • Alzheimer’s disease is the sixth-leading cause of death in the United States, and the fifth-leading cause of death among those age 65 and older. It also is a leading cause of disability and poor health.
  • Although deaths from other major causes have decreased significantly, official records indicate that deaths from Alzheimer’s disease have increased significantly. Between 2000 and 2015, deaths from Alzheimer’s disease as recorded on death certificates increased 123 percent, while deaths from the number one cause of death (heart disease) decreased 11 percent.
  • Among people age 70, 61 percent of those with Alzheimer’s are expected to die before the age of 80 compared with 30 percent of people without Alzheimer’s — a rate twice as high.

Increasing Cost Burden:

The report highlights that Alzheimer’s places a huge burden on the health care system, with annual costs exceeding a quarter of a trillion dollars.

In 2018, the direct costs to American society of caring for those with Alzheimer’s will total an estimated $277 billion, including $186 billion in Medicare and Medicaid payments. Unless something is done, in 2050, Alzheimer’s is projected to cost more than $1.1 trillion (in 2018 dollars). This dramatic rise includes more than four-fold increases both in government spending under Medicare and Medicaid and in out-of-pocket spending.

The costs of health care and long-term care for individuals with Alzheimer’s or other dementias are substantial. Dementia is one of the costliest conditions to society.

  • People with Alzheimer’s or other dementias have twice as many hospital stays per year as other older people.
  • Medicare beneficiaries with Alzheimer’s or other dementias are more likely than those without dementia to have other chronic conditions.
  • People with Alzheimer’s or other dementias make up a large proportion of all elderly people who receive adult day services and nursing home care.

The report further highlights that Early diagnosis of Alzheimer’s provides a number of important benefits to diagnosed individuals, their caregivers and loved ones, as well as society as a whole. The development of biomarkers for Alzheimer’s disease is making it possible to detect Alzheimer’s disease and provide an accurate diagnosis earlier than at any other time in history. In addition to providing significant medical, emotional and social benefits and facilitating participation in important clinical trials, early diagnosis enables individuals to prepare legal, financial and end-of-life plans while they are still cognitively able to make decisions and share their wishes.

 

About Pharmascroll:

Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.

To read more news about Alzheimer’s disease indication, visit https://pharmascroll.com/news-category/alzheimers/

 

News Source: https://www.alz.org/facts/

Image Source: https://consumer.healthday.com/cognitive-health-information-26/alzheimer-s-news-20/brain-pacemaker-might-help-slow-alzheimer-s-730606.html